NCT00205023已完成不适用
The Incidence of Disseminated Endometrial Cancer Cells During Sonohysterography and Their Functional Viability: a Prospective Study
适应症
干预措施
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 25
- 试验地点
- 1
- 主要终点
- determine the critical volume necessary to overcome tubal pressure and result in fluid dissemination during SHG
研究概览
简要总结
The purpose of study is to: 1) determine critical volume necessary to overcome tubal pressure and result in fluid dissemination and 2) evaluate functional viability of any disseminated tumor cells collected during SHG
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Other
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- Female
- 接受健康志愿者
- 否
入选标准
- •Stage I endometrial Cancer Disease
- •State IIA endometrial Cancer Disease
排除标准
- •Prior tubal ligation
- •Prior bilateral salpingectomy
研究组 & 干预措施
A
Experimental
干预措施: Sonohysterography (Procedure)
结局指标
主要结局
determine the critical volume necessary to overcome tubal pressure and result in fluid dissemination during SHG
时间窗: during surgery
次要结局
- evaluate the functional viability of any disseminated tumor cells collected during SHG(during surgery)
研究者
研究点 (1)
Loading locations...
相似试验
Unknown
不适用
Endometrial Volume as a Predictor of Endometrial Pathology in Perimenopausal Uterine Bleeding Endometrial Volume as a Predictor of Endometrial Pathology in Perimenopausal Uterine BleedingEndometrial DisorderNCT03351673Mansoura University100
招募中
不适用
Clinicopathological Analysis of Endometrial Carcinoma in the View of Old and New International Federation of Gynecology and Obestetrics (FIGO)ClinicopathologicalEndometrial CarcinomaFederation of Gynecology and ObestetricsNCT06632431Assiut University110
招募中
不适用
The Role of Endometrial Blood Flow in Endometrial CancerEndometrial CancerNCT05034991Far Eastern Memorial Hospital75
已完成
不适用
Intestinal Permeability and EndometriosisEndometriosisNCT03042923University of Tennessee46
撤回
1 期
Efficacy and Safety Study of Lurbinectedin and Dostarlimab in Cancer Patients: Protocol VHIO21001 - LiDerEndometrial CancerNCT06385548Vall d'Hebron Institute of Oncology15